These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10675504)

  • 21. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia.
    Halwani M; Mugabe C; Azghani AO; Lafrenie RM; Kumar A; Omri A
    J Antimicrob Chemother; 2007 Oct; 60(4):760-9. PubMed ID: 17673475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell.
    Drulis-Kawa Z; Dorotkiewicz-Jach A; Gubernator J; Gula G; Bocer T; Doroszkiewicz W
    Int J Pharm; 2009 Feb; 367(1-2):211-9. PubMed ID: 18952159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liposome-encapsulated antibiotics: preparation, drug release and antimicrobial activity against Pseudomonas aeruginosa.
    Lagacé J; Dubreuil M; Montplaisir S
    J Microencapsul; 1991; 8(1):53-61. PubMed ID: 1908898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the interaction between liposomal formulations and Pseudomonas aeruginosa.
    Jia Y; Joly H; Omri A
    J Liposome Res; 2010 Jun; 20(2):134-46. PubMed ID: 19831502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa.
    Madaras-Kelly KJ; Moody J; Larsson A; Baeker Hovde L; Rotschafer JC
    Chemotherapy; 1997; 43(2):108-17. PubMed ID: 9084919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits.
    Chetoni P; Burgalassi S; Monti D; Tampucci S; Tullio V; Cuffini AM; Muntoni E; Spagnolo R; Zara GP; Cavalli R
    Eur J Pharm Biopharm; 2016 Dec; 109():214-223. PubMed ID: 27789355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa.
    Alipour M; Suntres ZE; Omri A
    J Antimicrob Chemother; 2009 Aug; 64(2):317-25. PubMed ID: 19465435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incorporation of Farnesol Significantly Increases the Efficacy of Liposomal Ciprofloxacin against Pseudomonas aeruginosa Biofilms in Vitro.
    Bandara HM; Herpin MJ; Kolacny D; Harb A; Romanovicz D; Smyth HD
    Mol Pharm; 2016 Aug; 13(8):2760-70. PubMed ID: 27383205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition.
    Beaulac C; Clement-Major S; Hawari J; Lagace J
    J Microencapsul; 1997; 14(3):335-48. PubMed ID: 9147283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
    Meers P; Neville M; Malinin V; Scotto AW; Sardaryan G; Kurumunda R; Mackinson C; James G; Fisher S; Perkins WR
    J Antimicrob Chemother; 2008 Apr; 61(4):859-68. PubMed ID: 18305202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of intravitreally injected liposome-encapsulated tobramycin in normal rabbits.
    Kim EK; Kim HB
    Yonsei Med J; 1990 Dec; 31(4):308-14. PubMed ID: 2077755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions.
    Ernst J; Klinger-Strobel M; Arnold K; Thamm J; Hartung A; Pletz MW; Makarewicz O; Fischer D
    Eur J Pharm Biopharm; 2018 Oct; 131():120-129. PubMed ID: 30063969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
    Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
    Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel combination proliposomes containing tobramycin and clarithromycin effective against Pseudomonas aeruginosa biofilms.
    Ye T; Sun S; Sugianto TD; Tang P; Parumasivam T; Chang YK; Astudillo A; Wang S; Chan HK
    Int J Pharm; 2018 Dec; 552(1-2):130-138. PubMed ID: 30267753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of extensively drug-resistant Pseudomonas aeruginosa osteomyelitis using a colistin- and tobramycin-impregnated PMMA spacer.
    Krajewski J; Bode-Böger SM; Tröger U; Martens-Lobenhoffer J; Mulrooney T; Mittelstädt H; Russlies M; Kirchner R; Knobloch JK
    Int J Antimicrob Agents; 2014 Oct; 44(4):363-6. PubMed ID: 25182711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
    Yadav R; Bulitta JB; Schneider EK; Shin BS; Velkov T; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study.
    Rukholm G; Mugabe C; Azghani AO; Omri A
    Int J Antimicrob Agents; 2006 Mar; 27(3):247-52. PubMed ID: 16472992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of AMP2041 against human and animal multidrug resistant Pseudomonas aeruginosa clinical isolates.
    Cabassi CS; Sala A; Santospirito D; Alborali GL; Carretto E; Ghibaudo G; Taddei S
    Ann Clin Microbiol Antimicrob; 2017 Mar; 16(1):17. PubMed ID: 28335779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption.
    Loose M; Naber KG; Shields P; Reinhart H; Wagenlehner FME
    Int J Antimicrob Agents; 2018 Mar; 51(3):422-426. PubMed ID: 29158143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.